Opens in a new tab

10x Genomics v Curio Bioscience (CFI, 8 August 2024)

Date8 August 2024
CourtCFI
DivisionDüsseldorf (DE) Local Division
Type of actionApplication RoP262A
Registry referenceApp_41690/2024 · ORD_42284/2024
PartiesCurio Bioscience, Inc v. 10x Genomics, Inc.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 8 August 2024 (UPC_CFI_140/2024, ACT_15774/2024, App_41690/2024), the judge-rapporteur of the Düsseldorf Local Division classified as confidential under Rule 262A RoP Curio Bioscience’s unredacted Statement of Defence, its updated version and two exhibits, in 10x Genomics’ infringement action on EP 2 697 391. Access is granted to two named representatives of 10x Genomics, their teams and named employees. The order clarifies how it relates to the orders made in the earlier provisional measures proceedings (UPC_CFI_463/2023).

Question

Do confidentiality orders made in summary proceedings carry over automatically to the main action, and on what basis can the access circle be widened there?

Decision

Orders made in summary proceedings do not preclude a new order in the main action, and the parties may seek different terms there, as the main action calls for a different balance between the right to be heard, speed and confidentiality (paragraph 3). As confidentiality was not seriously disputed, the information is protected (paragraph 4). There is normally no reason to cap the number of representatives or to confine access to UPC representatives, but Rule 262A.6 RoP requires access to be no wider than necessary and accountability to be clear: the named representatives answer for their teams (paragraph 5). Once a party has named its persons, the other party must justify any objection, which Curio did not do for the three employees (paragraph 6).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 58
Rules of Procedure
Rule 262A
Other provisions
Directive (EU) 2016/943, Art. 9
Case law cited
Avago v Tesla Germany, Hamburg Local Division, 3 November 2023, 10x Genomics v Curio Bioscience, Düsseldorf Local Division, 23 February 2024, UPC_CFI_463/2023, 10x Genomics v Curio Bioscience, Düsseldorf Local Division, 11 March 2024, 10x Genomics v Curio Bioscience, Düsseldorf Local Division, 22 March 2024, Aylo Freesites v DISH, Mannheim Local Division, 3 July 2024

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Confidentiality club.

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Application RoP262A
Outcome (Dhenne Avocats summary)
Le mémoire en défense et deux pièces de Curio sont classés confidentiels. L'accès est ouvert à deux représentants nommés de 10x Genomics, à leurs équipes et à des salariés désignés, une nouvelle ordonnance étant possible au fond.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 697 391
Method and product for localised or spatial detection of nucleic acid in a tissue sample
recorded proprietor: Spatial Transcriptomics AB
Mentioned in the analysis (role not qualified)
Also mentioned in 28 other decision(s): 10x Genomics v Curio Bioscience (CFI, ORD_598272/2023, 30 April 2024) · 10x Genomics v Curio Bioscience (CFI, UPC_CFI_658/2025, 2 February 202 · 10x Genomics v Curio Bioscience (CFI, UPC_CFI_657/2025, 2 February 202 · 10x Genomics v Curio Bioscience (CFI, 5 August 2025) · 10x Genomics v Curio Bioscience (CFI, 4 August 2025) · 10x Genomics v Curio Bioscience (CFI, 16 June 2025) · 10x Genomics v Curio Bioscience (CFI, 4 June 2025) · 10x Genomics v Curio Bioscience (CFI, 2 May 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.